RPG Life Sciences Ltd

Ticker: RPGLIFE
Decent 68/100

☆ Add to Watchlist

Investing Reference

Price
2291.00
Market Cap
3789.09
Debt/Equity
0.0000
ROE %
40.478
PB
7.1421
Promoter %
72.951
Pledge %
0.000
1Y Rev Growth %
29.831
5Y Rev Growth %
15.247
NP Margin %
23.952
NP Margin 5Y Avg %
14.754

Trading Reference

1M Return %
-3.594
6M Return %
5.664
1Y Return %
-19.004
% Away 52W High
29.854
% Away 52W Low
24.850
Daily Volume
5556
Investment Verdict
Hold
Score 68/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 25/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.

AI Probability Statement

Probability Statement

RPG Life Sciences Ltd is currently trading near a key support level, with the 50-day EMA indicating a potential upward trend if it holds. Resistance is observed at recent highs, suggesting a range-bound scenario. Volume has been moderate, indicating cautious investor sentiment. Overall, there is a moderate probability of upward movement in the medium term, contingent on breaking resistance levels.
Upside Probability: 15%   |   Downside Probability: 10%

Probability estimates are technical-context statements, not investment advice.

More Options

Business Overview

RPG Life Sciences Ltd is a prominent player in the Indian pharmaceutical sector, dedicated to developing high-quality medicines that enhance patient care. Catering to healthcare providers and patients alike, the company focuses on innovative solutions across various therapeutic areas. With a commitment to research and development, RPG Life Sciences is poised to address unmet medical needs, making a significant impact on public health. Their robust portfolio and strong distribution network ensure accessibility and reliability in the market.

  • Established leader in the Indian pharmaceutical industry
  • Focus on research and innovative healthcare solutions
  • Diverse portfolio across multiple therapeutic areas
  • Strong commitment to quality and patient care
  • Wide distribution network for enhanced accessibility

Investment Thesis

RPG Life Sciences Ltd stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. This combination positions the company for sustainable growth and long-term value creation, making it a compelling investment opportunity.

  • Strong backing from the reputable RPG Group enhances credibility.
  • Significant growth potential in digital services sector.
  • Attractive valuation metrics compared to industry peers.
  • Focus on innovation and R&D to drive future growth.
  • Strong financial performance and consistent dividend payouts.

Opportunity vs Risk

Opportunities
  • Growing demand for healthcare products
  • Strong pipeline of new drugs
  • Expansion into international markets
  • Strategic partnerships with healthcare providers
Risks ⚠️
  • Regulatory changes affecting approvals
  • Intense competition in the sector
  • Dependence on a few key products
  • Fluctuating raw material costs

Peer Perspective

RPG Life Sciences Ltd trades at a modest discount to peers like Sun Pharmaceutical and Dr. Reddy's Laboratories, with potential for rerating contingent on sustained margin stability and improved growth metrics.

Future Outlook

RPG Life Sciences Ltd is well-positioned for growth, driven by its innovative product pipeline and expanding market presence; however, successful execution and effective cost control will be crucial to fully realize its potential.

AI FAQs for Retail Users

  • Q: What does RPG Life Sciences Ltd do?
    A: RPG Life Sciences Ltd is involved in pharmaceutical manufacturing and research, focusing on generic and specialty medicines.
  • Q: Is RPG Life Sciences Ltd a good investment?
    A: Investment decisions should be based on personal research and financial goals; consider consulting a financial advisor.
  • Q: What are the recent developments for RPG Life Sciences Ltd?
    A: Recent developments include new product launches and partnerships, enhancing its market presence and growth potential.
  • Q: How can I buy shares of RPG Life Sciences Ltd?
    A: You can purchase shares through a stockbroker or an online trading platform that offers access to Indian stock markets.
  • Q: What are the risks associated with investing in RPG Life Sciences Ltd?
    A: Risks include market volatility, regulatory changes, and competition within the pharmaceutical industry.
📊 Stock Investment Checklist (100 Points)
RPG Life Sciences Ltd • Updated: 2025-09-18 00:49:07
  • 10
    Business
    High
    The sector is growing with increasing demand for pharmaceuticals, but competition is high.
  • 10
    Growth
    High
    Consistent revenue growth observed over the last few years, but profit margins are fluctuating.
  • 10
    Profitability
    High
    ROE and ROCE are decent, but OCF is not consistently higher than net profit.
  • 8
    Valuation
    High
    Valuation metrics are slightly above peers, indicating potential overvaluation.
  • 7
    Balance
    High
    Debt levels are manageable, but liquidity ratios are on the lower side.
  • 6
    Governance
    Good
    Promoter holding is stable, but there are concerns regarding transparency in disclosures.
  • 5
    Drivers
    Good
    Growth drivers are present, but execution risks remain significant.
  • 5
    Technicals
    Good
    Market sentiment is neutral with low liquidity and mixed price action.
Final Score & Verdict
Score 68 / 100 • Decent
RPG Life Sciences Ltd shows potential for growth but faces challenges in profitability and valuation metrics.

AI Confidence Score

Instead of just “overall score,” broken into categories:

  • Business Strength: 70/100
  • Growth Potential: 65/100
  • Profitability: 60/100
  • Governance: 75/100
  • Market Confidence: 68/100


More Like This

Latest News

More ↗

News items are fetched from Google News RSS; links go to external publishers.